Gedeon Richter expects Lenzetto return as Richter Gedeon stock costs EUR 33.62

Published on 10/09/2026 at 12:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 8.70 percent in the first half in constant currency. Richter Gedeon stock costs EUR 33.62 on October 9 after EUR 33.42, plus 0.60 percent.

Gedeon Richter expects Lenzetto to return to Spanish pharmacies in the second half of November 2026.
First-half constant-currency revenue rose 8.70 percent and Clean EBIT increased 21.00 percent.
Richter Gedeon stock was EUR 33.62 at Lang & Schwarz on October 9, 2026, plus 0.60 percent versus EUR 33.42.
The next earnings date is November 10, 2026.

Richter Gedeon, HU0000123096, Illustration mit AI erstellt.

Richter Gedeon stock was trading at EUR 33.62 at Lang & Schwarz on October 9, 2026 at 12:43 p.m. CEST, plus 0.60 percent versus the EUR 33.42 prior close. Gedeon Richter expects its menopause treatment Lenzetto to return to Spanish pharmacies in the second half of November 2026, as Euronews reported on October 7, 2026.

Three milestones shape the stock

On August 7, 2026, Gedeon Richter reported constant-currency revenue growth of 8.70 percent in the first half and a 21.00 percent increase in constant-currency Clean EBIT, according to Yahoo Finance.

In September 2026, the average analyst target cited by Simply Wall St rose to HUF 13,038 from HUF 12,093, a 7.80 percent increase across seven analysts. On October 7, 2026, the Lenzetto update added a near-term supply milestone, while the company said worldwide constraints could limit coverage of demand in 2027, Euronews reported.

What does the supply update change?

Lenzetto links Richter's women’s healthcare business to a production constraint rather than a change in product quality. Euronews reported that demand exceeded manufacturing capacity and that the applicator supply also needed expansion, with a new plant and production line part of the response.

The financial backdrop is more constructive. The August 2026 earnings call said 2026 pharma Clean EBIT was expected to grow at a double-digit rate on a constant-currency basis, while reported first-half revenue reached HUF 151.8 billion, up 3.00 percent. Net profit was HUF 103.5 billion after foreign-exchange pressure, and the company reported HUF 4.5 billion of restructuring costs in the first half, according to Yahoo Finance.

Next dates and the trading view

The next scheduled earnings date is November 10, 2026, according to Simply Wall St. The second-half November 2026 Lenzetto supply return is the next operating milestone identified by Euronews.

At Lang & Schwarz, the stock was trading at EUR 33.62 on October 9, 2026 at 12:43 p.m. CEST, up 0.60 percent versus the EUR 33.42 prior close from October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of Richter Gedeon stock.